Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection

JAMA Netw Open. 2020 Nov 2;3(11):e2025577. doi: 10.1001/jamanetworkopen.2020.25577.

Abstract

Importance: Ehrlichiosis cases in the US have increased more than 8-fold since 2000. Up to 57% of patients with ehrlichiosis require hospitalization and 11% develop a life-threatening complication; however, risk factors for serious disease are not well documented.

Objective: To examine risk factors associated with severe ehrlichiosis.

Design, setting, and participants: An analytic cross-sectional study of patients diagnosed with ehrlichiosis by polymerase chain reaction (PCR) between January 1, 2007, and December 31, 2017, was conducted in a single tertiary-care center in a region endemic for ehrlichiosis. Analysis was performed from February 27, 2018, to September 9, 2020. A total of 407 positive Ehrlichia PCR results were identified from 383 unique patients, with 155 unique patients meeting study criteria. Patients hospitalized at other institutions who had a positive Ehrlichia PCR performed as a reference test (n = 222) were excluded as no clinical data were available. Electronic medical record review was performed to collect demographic, clinical, laboratory, treatment, and outcomes data. Cases were excluded when there were insufficient clinical data to assess the severity of illness (n = 3) and when the clinical illness did not meet the case definition for ehrlichiosis (n = 3).

Exposures: Date of presentation, onset of symptoms, date of PCR testing, date of treatment initiation, site of care, age, birth sex, race/ethnicity, Charlson Comorbidity Index, trimethoprim with sulfamethoxazole use within the prior 2 weeks, and immunosuppression.

Main outcomes and measures: Requirement for intensive care unit (ICU) admission.

Results: Of the 155 patients who met inclusion criteria, 99 patients (63.9%) were men, and 145 patients (93.5%) identified as non-Hispanic White; median age was 50 years (interquartile range, 23-64 years). Intensive care unit admission was indicated in 43 patients (27.7%), 94 patients (60.6%) were hospitalized on general medical floors, and 18 patients (11.6%) received care as outpatients. In adjusted analysis, time to treatment initiation was independently associated with an increased risk for ICU admission (adjusted prevalence ratio [aPR], 1.09; 95% CI, 1.04-1.14; P < .001). Documentation of tick exposure was independently associated with a decreased risk for ICU admission (aPR, 0.54; 95% CI, 0.34-0.86; P = .01). There appeared to be a nonsignificant change toward a decreased need for ICU care among immunosuppressed persons (aPR, 0.51; 95% CI, 0.26-1.00; P = .05).

Conclusions and relevance: This study suggests that delay in initiation of doxycycline therapy is a significant factor associated with severe ehrlichiosis. Increased recognition of infection by front-line clinicians to promote early treatment may improve outcomes associated with this increasingly common and life-threatening infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Ambulatory Care
  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Delayed Diagnosis / statistics & numerical data*
  • Documentation
  • Doxycycline / therapeutic use*
  • Dyspnea / physiopathology
  • Ehrlichiosis / drug therapy*
  • Ehrlichiosis / immunology
  • Ehrlichiosis / physiopathology
  • Exanthema / physiopathology
  • Female
  • Hospitalization
  • Humans
  • Immunocompromised Host / immunology
  • Infant
  • Intensive Care Units / statistics & numerical data*
  • Male
  • Middle Aged
  • Protective Factors
  • Risk Factors
  • Severity of Illness Index
  • Tick Bites
  • Time-to-Treatment / statistics & numerical data*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Doxycycline